A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder

Psychopharmacology

Volumn 231, Issue 6, 2014, Pages 1251-1265

  Jucaite, Aurelija ^a,e   Öhd, John ^a,f   Potter, Alexandra S ^b   Jaeger, Judith ^c,g   Karlsson, Pär ^a,h   Hannesdottir, Kristin ^a,c   Boström, Emma ^a   Newhouse, Paul A ^b,d   Paulsson, Björn ^a,i  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF VERMONT   (United States)

^c ASTRAZENECA   (United Kingdom)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Shire AG   (Switzerland)

^g Scientific Division   (United States)

^h Central Statistical Bureau of Sweden   (Sweden)

ⁱ BIOVITRUM AB   (Sweden)

Author keywords

ADHD; AZD1446; Cognition; Nicotinic receptors

Indexed keywords

AZD 1446; NICOTINE; NICOTINIC AGENT; PLACEBO; TC 6683; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; EPISODIC MEMORY; ERECTILE DYSFUNCTION; EXECUTIVE FUNCTION; FEMALE; HEADACHE; HUMAN; INSOMNIA; LEARNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; WORKING MEMORY;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BICYCLO COMPOUNDS, HETEROCYCLIC; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, NICOTINIC; TIME FACTORS; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896711452     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3116-7     Document Type: Article

References (66)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (DSM-IV-TR). American Psychiatric Association, Washington, DC
2. Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, Briggs CA, Gopalakrishnan M (2009) Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination. Biochem Pharmacol 78:844-851
3. Andrews-Hanna JR, Mackiewicz Seghete KL, Claus ED, Burgess GC, Ruzic L, Banich MT (2011) Cognitive control in adolescence: neural underpinnings and relation to self-report behaviors. PLoSOne 6(6):e21598
4. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD (2012) Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl) 219:715-725
5. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL et al (1994) (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J Pharmacol Exp Ther 270:310-318 (Pubitemid 24229641)
6. Bain EE, Apostol G, Sangal RB, Robieson WZ, McNeill DL, Abi-Saab WM, Saltarelli MD (2012) A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 73:783-789
7. Bernfort L, Nordfeldt S, Persson J (2008) ADHD from a socioeconomic perspective. Acta Paediatrica 97:239-245
8. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL et al (2009) Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacol 34:282-289
9. Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Safety 20:109-117 (Pubitemid 29101275)
10. Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R (2006) Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 10(3):117-123
11. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH et al (1996) Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 32:67-73 (Pubitemid 26176204)
12. Conners CK, Erhardt D, Sparrow E (2004) Conners' Adult ADHD Rating Scales. Multi-Health Systems Inc, North Tonawanda, NY
13. Cubillo A, Halari R, Smith A, Taylor E, Rubia K (2012) A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex 48(2):194-215
14. Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191:919-929 (Pubitemid 46399143)
15. Eagle DM, Robbins TW (2003) Inhibitory control in rats performing a stop-signal Reaction-time task: effects of lesions of the medial striatum and D-amphetamine. Behav Neurosci 117:1302-1317 (Pubitemid 37549431)
16. Faraone SV, Biederman J, Monuteaux M, Seidman L (2001) Attention deficit hyperactivity disorder and learning disability: a prospective four year follow-up study. J of Atten Disorders 3:23-25
17. Greenwood PM, Parasuraman R, Espeseth T (2012) A cognitive phenotype for a polymorphism in the nicotinic receptor gene CHRNA4. Neuroscience and Biobehav Rev 36:1331-1341
18. Grimwood S, Hartig PR (2009) Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Therapeut 122:281-301
19. Grottick AJ, Wyler R, Higgins GA (2001) A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task. Pharmacol Biochem Behav 70:505-513 (Pubitemid 34131645)
20. Guillem K, Bloem B, Poorthuis RB, Loos M, Smit AB, Maskos U, Spijker S, Mansvelder HD (2011) Nicotinic acetylcholine receptor β 2 subunits in the medial prefrontal cortex control attention. Science 333(6044):888-891
21. Guy W (1976) ECDEU Assessment manual for psychopharmacology - revised (DHEW Publ. No. ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp 218-222
22. Hahn B, Sharples CGV, Wonnacott S, Shoaib M, Stolerman IP (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacol 44:1054-1067 (Pubitemid 36570430)
23. Howe WM, Ji J, Parikh V, Williams S, Mocaër E, Trocmé- Thibierge C, Sarter M (2010) Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 35(6):1391-1401
24. Humby T, Wilkinson (2011) Assaying dissociable elements of behavioral inhibition and impulsivity: translational utility of animal models. Current Opinion in Pharmacol 11:534-539
25. th CINP World Congress of Nueropsychopharmacology, 3-7 June, 2012
26. Klassen AF, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541-547 (Pubitemid 41655750)
27. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH et al (1996) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacol 123:55-63
28. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633-640
29. Lim YY, Prang KH, Cysique L, Pietrzak RH, Snyder PJ, Maruff P (2009) A method for cross-cultural adaptation of a verbal memory assessment. Behav Res Meth 41:1190-1200
30. Logan GD, Cowan WB, Davis KA (1984) On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform 10:276-291
31. Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA (2009) Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem Pharmacol 78:795-802
32. Mazurov AA, Miao L, Bhatti BS, Strachan JP, Akireddy S, Murthy S, Kombo D, Xiao YD, Hammond P, Zhang J, Hauser TA, Jordan KG, Miller CH, Speake JD, Gatto GJ, Yohannes D (2012) Discovery of 3-(5-chloro-2-furoyl)-3,7- diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. J Med Chem 55:9181-994
33. McGaughy J, Decker MW, Sarter M (1999) Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl) 144:175-182 (Pubitemid 29264434)
34. McNair DM, Lorr M, Droppelman LF (1971) Manual for the profile of mood states. Educational and Industrial Testing Service, San Diego
35. Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA (2008) Greater nicotinic acetylcholine receptor density in smokers than in non-smokers: a PET study with 2-18F-FA-85380. J Nucl Med 49:1628-1635
36. Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D'souza DN, Schuh LM, Allen AJ (2009) Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child and Adolescent Psych 48:1165-1172
37. Perry DC, Dávila-García MI, Stockmeier CA, Kellar KJ (1996) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exper Therapeut 289:1545-1552 (Pubitemid 29246689)
38. Pimlott SL, Piggott M, Owens J et al (2004) Nicotinic acetylcholine receptor distribution in Alzheimer 's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacol 29:108-116 (Pubitemid 38068020)
39. Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/ hyperactivity disorder across the lifespan. Cur Opin Psych 20:386-392 (Pubitemid 46889666)
40. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942-948 (Pubitemid 46972911)
41. Potter AS, Newhouse PA (2004) Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacol (Berl) 176:182-194 (Pubitemid 39517948)
42. Potter AS, Newhouse PA (2006) Bucci DJ (2006) Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/ hyperactivity disorder? Behav Brain Res 175:201-211 (Pubitemid 44750245)
43. Potter AS, Newhouse PA (2008) Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav 88:407-417 (Pubitemid 350266783)
44. Potter AS, Bucci DJ, Newhouse PA (2012) Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. Psychopharmacol (Berl) 220:331-340
45. Potter AS, Dunbar G, Mazzulla E, Hosford D, Newhouse PA (2013) Nicotinic agonist treatment with AZD3480 improves behavioral inhibition and clinical measures in adult Attention Deficit/Hyperactivity Disorder (manuscript in review)
46. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ (1998) Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) 136:50-58
47. Rezvani AH, Cauley M, Sexton H, Xiao Y, Brown ML, Paige MA, McDowell BE, Kellar KJ, Levin ED (2011) Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) 215:621-630
48. Rezvani AH, Cauley MC, Johnson EC, Gatto GJ, Levin ED (2012) Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. Psychopharmacology (Berl) 223:251-258
49. Sarter M, Paolone G (2011) Deficits in attentional control: cholinergic mechanismsand circuitry-based treatment approaches. Behav Neurosci 125:825-835
50. Sarter M, Gehring WJ, Kozak R (2006) More attention must be paid: the neurobiology of attentional effort. Brain Res Rev 51:145-160 (Pubitemid 43902969)
51. Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, Lester HA (2011) Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. J Gen Physiol 137:59-79
52. 18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl Radiat Isot 61:1235-1240
53. Szeliga KT, Jordan KG, Hauser TA, Mazurov AA, Yohannes D, Rezvani AH, Levin ED, von Euler G, Johnson EC, Gatto GJ. (2012) AZD1446 (TC-6683), a novel alpha4beta2 nAChR agonist with cognitive-enhancing properties. Abstract. Society for Neuroscience Meeting, Oct 13-17, New Orleans
54. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63:992-997 (Pubitemid 35388057)
55. Todd RD, Lobos EA, Sun LW, Neuman RJ (2003) Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry 8:103-108 (Pubitemid 36188579)
56. Tomasi D, Volkow ND (2012) Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry 71:443-450
57. Ueno K, Togashi H, Matsumoto M, Ohashi S, Saito H, Yoshioka M (2002) Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder. J Pharmacol Exp Ther 302:95-100 (Pubitemid 34680426)
58. von Euler G, Bertrand D, Johnson EC (2011) Comparison of pharmacologic properties of AZD3480 and AZD1446 on neuronal nicotinic receptor subtypes. Biochem Pharmacol 82:1026
59. von Euler G, Bertrand D, Gatto GJ, Johnson EC (2012) Agonistic and desensitization properties of clinically tolerated compounds on neuronal nicotinic receptor subtypes. Abstract 532.16/B43, Society for Neuroscience Annual Conference, New Orleans, USA
60. Wells GB (2008) Structural answers and persistent questions about how nicotinic receptors work. Front Biosci 13:5479-510
61. Wickens JR, Hyland BI, Tripp G (2011) Animal models to guide clinical drug development in ADHD: lost in translation? Br J Pharmacol 164:1107-1128
62. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931-1937
63. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA (2006) ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59:1065-1070 (Pubitemid 43849655)
64. Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olson E, Robieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD (2011) Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolescent Psych 50:73-84
65. Winstanley CA (2011) The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol 164:1301-1321
66. Young JW, Meves JM, Geyer MA (2013 Mar 1) Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res 240:119-33